• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by AnPac Bio-Medical Science Co. Ltd.

    7/27/23 4:10:19 PM ET
    $ANPC
    Medical Specialities
    Health Care
    Get the next $ANPC alert in real time by email
    SC 13D 1 ea182471-13dimmensus_fresh2.htm SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.     )*

     

     

    Fresh2 Group Limited

    (Name of Issuer)

     

    Class A Ordinary Shares, par value US$0.01

    (Title of Class of Securities)

     

    Class A Ordinary Shares: G0393E107

    (CUSIP Number)

     

    Haohan Xu

    650 Fifth Avenue, Suite 2416

    New York, NY 10019-6108

    646-409-6505

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    July 17, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G0393E107 SCHEDULE 13D Page 2 of 6

     

    (1)

    Names of Reporting Persons

     

    Haohan Xu

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ☐ (b) ☐

    (3)

    SEC use only

     

    (4)

    Source of Funds (See Instructions)

     

    OO/PF (1) (2)

    (5)

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     

    (6)

    Citizenship or Place of Organization

     

    U.S.A.

    Number of (7)

    Sole voting power

     

    71,774,679 (1) (2)

    shares

    beneficially

    owned by

    (8)

    Shared voting power

     

     

    each

    reporting

    person

    (9)

    Sole dispositive power

     

    71,774,679 (1) (2)

    with: (10)

    Shared dispositive power

     

     

    (11)

    Aggregate amount beneficially owned by each reporting person

     

    71,774,679 (1) (2)

    (12)

    Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ☐

    (13)

    Percent of class represented by amount in Row (11)

     

    24.37% (1) (2)

    (14)

    Type of reporting person (see instructions)

     

    IN

     

    (1)Consists of 66,334,259 Class A Ordinary Shares held by Immensus LLC (“Immensus”). Mr. Haohan Xu is the sole owner and manager of Immensus. Mr. Haohan Xu is deemed to beneficially own the entirety of the 66,334,259 Class A Ordinary Shares held by Immensus. The aforementioned Class A Ordinary Shares were issued to Immenus pursuant to the terms of a stock purchase agreement (the “July 2023 SPA”), dated July 17, 2023, whereby Immenus was issued 66,334,259 Class Ordinary A Shares by the Issuer in consideration for 73,823,182 shares of common stock of Roxe Holding Inc.

     

    (2)Consists of 5,440,420 Class A Ordinary Shares held directly by Mr. Haohan Xu.

     

     

     

     

    CUSIP No. G0393E107 SCHEDULE 13D Page 3 of 6

     

    (1)

    Names of Reporting Persons

     

    Immensus LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ☐ (b) ☐

    (3)

    SEC use only

     

    (4)

    Source of Funds (See Instructions)

     

    OO (1)

    (5)

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     

    (6)

    Citizenship or Place of Organization

     

    New York

    Number of (7)

    Sole voting power

     

    66,334,259

    shares

    beneficially

    owned by

    (8)

    Shared voting power

     

     

    each

    reporting

    person

    (9)

    Sole dispositive power

     

    66,334,259

    with: (10)

    Shared dispositive power

     

     

    (11)

    Aggregate amount beneficially owned by each reporting person

     

    66,334,259

    (12)

    Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    ☐

    (13)

    Percent of class represented by amount in Row (11)

     

    22.53%

    (14)

    Type of reporting person (see instructions)

     

    OO

     

    (1)The Class A Ordinary Shares were acquired pursuant to the terms of the July 2023 SPA, whereby Immenus was issued 66,334,259 Class Ordinary A Shares by the Issuer in consideration for 73,823,182 shares of common stock of Roxe Holding Inc.

     

     

     

     

    CUSIP No. G0393E107 SCHEDULE 13D Page 4 of 6

     

    Item 1. Security and Issuer.

     

    This Schedule 13D is filed (this “Schedule 13D”) by the Reporting Persons (as identified above and defined below) with respect to the ordinary shares US$0.01 (“Shares”) of Fresh2 Group Limited, a British Virgin Islands company, with its principal executive offices located at 650 Fifth Avenue, Suite 2416, New York, NY 10019-6108.

     

    Item 2. Identity and Background.

     

    (a) This Schedule 13D is being filed by the following persons (each a “Reporting Person” and, collectively, the “Reporting Persons”):

     

    Mr. Haohan Xu and

    Immensus LLC (“Immensus”).

     

    (b) Haohan Xu’s business address is 650 Fifth Avenue Ste 2416, New York, NY 10019. Immensus’ business address is 2 La Colline Dr, Mill Neck, NY 11765

     

    (c) Haohan Xu is a director, chief executive officer and chairman of the board of directors of the Issuer. Immensus’ principal business is investing in securities.

     

    (d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) Haohan Xu is a citizen of the United States of America. Immensus is a limited liability company formed in New York.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Haohan Xu has acquired all of the Shares beneficially owned by him pursuant to a share purchase agreement dated February 7, 2023, (the “Ecommerce SPA”) with the Issuer purchasing the entirety issued and outstanding equity interests of Fresh 2 Ecommerce Inc. from Mr. Haohan Xu in exchange for 5,440,420 Class A Ordinary Shares of the Issuer.

     

    Immensus has acquired all of the Shares beneficially owned by it pursuant to the terms of the July 2023 SPA, whereby Immenus was issued 66,334,259 Class Ordinary A Shares by the Issuer in consideration for 73,823,182 shares of common stock of Roxe Holding Inc.

     

    Item 4. Purpose of Transaction.

     

    The Reporting Person serves as Chairman of the Issuer, is a member of the board of directors of the Issuer and a chief executive officer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others. Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D.

     

    Immensus has acquired all of the Shares beneficially owned by it pursuant to the terms of the July 2023 SPA, whereby Immenus was issued 66,334,259 Class Ordinary A Shares by the Issuer in consideration for 73,823,182 shares of common stock of Roxe Holding Inc.

     

     

     

     

    CUSIP No. G0393E107 SCHEDULE 13D Page 5 of 6

     

    Item 5. Interest in Securities of the Issuer.

     

    (a) Incorporated by reference to Items 11 and 13 of the Cover Page.

     

    (b) Incorporated by reference to Items 7-10 of the Cover Page.

     

    (c) The Reporting Persons have not effected any transactions of the Issuer’s Ordinary shares during the 60 days preceding the date of this Schedule 13D.

     

    (d) None

     

    (e) N/A

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    Stock Purchase Agreement – Pursuant to the terms of a stock purchase agreement (the “July 2023 SPA”), dated July 17, 2023, whereby Immenus was issued 66,334,259 Class Ordinary A Shares by the Issuer in consideration for 73,823,182 shares of common stock of Roxe Holding Inc. A copy of the July 2023 SPA is attached to this Schedule 13D as Exhibit 2 and incorporated herein by reference.

     

    Item 7. Material to Be Filed as Exhibits.

     

    Exhibit
    Number
      Description
    1.   Joint Filing Agreement.
    2.   Stock Purchase Agreement, dated July 17, 2023 (Incorporated herein by reference to the exhibit 10.1 to the Issuer’s Current Report Form 6-K, filed with the SEC on July 21, 2023)

     

     

     

     

    CUSIP No. G0393E107 SCHEDULE 13D Page 6 of 6

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: July 27, 2023 HAOHAN XU
         
      /s/ Haohan Xu
         
      IMMENSUS LLC
         
      By: /s/ Haohan Xu
      Name:  Haohan Xu
      Title: Manager

     

     

     

    Get the next $ANPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANPC
    SEC Filings

    See more
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/16/24 4:36:43 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/1/24 4:01:33 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      1/29/24 5:29:36 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

      Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has tra

      5/19/23 12:55:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and the Company's investor rela

      5/16/23 5:00:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Reports Fiscal Year 2022 Annual Financial Results

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021.  Gross margi

      5/16/23 4:15:00 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Liang Zhijun

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:31:07 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Zhao Zhigang

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:29:59 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Li Xiaoyu

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:28:09 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Leadership Updates

    Live Leadership Updates

    See more
    • AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

      PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the board of directors appointed Jiawen Kang as a member of the board of directors of the Company (the "Board") and a member of the Audit Committee and Nominating Committee. On that date, the Company also appointed Yuyang Cui as (a) Co-Chairman of the Board and (b) Co-Chief Executive Officer of the Company. As Co-CEO of the Company, Yuyang Cui will be primarily responsible for (i) searching and presentin

      8/5/22 4:45:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees

      PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company's Members approved Written Resolutions of a Majority of the Members (the "Resolutions") on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a general meeting in accordance with British Virgin Islands law, which allows Member's resolution

      7/18/22 6:39:14 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member

      PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. Aidong Chen has joined the Company as its board director, Chief Executive Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replace

      4/8/22 9:12:52 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13D - Fresh2 Group Ltd (0001786511) (Subject)

      7/27/23 4:10:19 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      3/24/23 6:09:00 AM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by AnPac Bio-Medical Science Co. Ltd. (Amendment)

      SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      10/12/22 4:45:23 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Financials

    Live finance-specific insights

    See more
    • AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider

      NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commer

      2/15/23 8:00:00 AM ET
      $ANPC
      Medical Specialities
      Health Care